Overview

Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome

Status:
Not yet recruiting

Trial end date:
2026-05-02

Target enrollment:

Participant gender:

Summary

This study is evaluating the efficacy of cabazitaxel and hormonal treatment as neoadjuvant treatment for patients with clinically operable disease suitable for surgery, and a high risk of relapse after surgery

Phase:

Phase 2

Details

Lead Sponsor:

The Clatterbridge Cancer Centre NHS Foundation Trust

Collaborator:

University of Liverpool